Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low – Here’s What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week low on Monday . The company traded as low as $13.46 and last traded at $13.55, with a volume of 20362 shares. The stock had previously closed at $14.38.

Wall Street Analyst Weigh In

A number of analysts have weighed in on BCAX shares. Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Morgan Stanley started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright initiated coverage on shares of Bicara Therapeutics in a research note on Friday, December 6th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Buy” and an average price target of $43.00.

Bicara Therapeutics Trading Down 9.4 %

The company has a fifty day moving average price of $19.28.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). On average, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BCAX. RA Capital Management L.P. bought a new position in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $177,169,000. FMR LLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Braidwell LP purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $42,219,000. Janus Henderson Group PLC purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $21,225,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.